Loading organizations...
§ Private Profile · 59 Everett Street, Natick
Biopharmaceutical company developing TNF inhibitor anti-inflammatory treatments for sciatica and disk herniation.
Key people at BioAssets Development Corporation.
BioAssets Development Corporation is a Wellesley, Massachusetts-based private biopharmaceutical company that pioneers novel spine indications for biologic drugs, specifically focusing on antibody-based anti-inflammatory treatments for sciatica and disk herniation. The enterprise develops tumor necrosis factor (TNF) inhibitor therapies designed to address the underlying biological causes of severe spinal pain. Funded initially through private venture capital investments, the firm successfully advanced its primary clinical candidate, known as CEP-37247, through early developmental stages. In October 2009, the organization entered into a strategic option agreement with the larger pharmaceutical corporation Cephalon to further advance this specific sciatica treatment. This partnership ultimately culminated in Cephalon fully acquiring the biotechnology firm to integrate these specialized spinal therapies into its broader clinical pipeline. BioAssets Development Corporation was founded in 2005 by former chief executive officer James Gorman and former chairman Robert Kamen.
Key people at BioAssets Development Corporation.
BioAssets Development Corporation is a small, private biomedical company focused on developing *spine indications* for biologic drugs—most notably a program to treat sciatica using TNF‑inhibitor approaches—and was the subject of an option/acquisition by Cephalon in 2009–2010 aimed at advancing epidural TNF inhibitor therapy for radicular pain (sciatica).[2][1]
High-Level Overview
Origin Story
Core Differentiators
Role in the Broader Tech/Healthcare Landscape
Quick Take & Future Outlook
Limitations and notes